Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12068-12069
10.1182/blood-2022-158599